Ivabradine. Best avoided in stable angina

Prescrire International

Volumn 16, Issue 88, 2007, Pages 53-56

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

4 (N ETHYL N PHENYLAMINO) 1,2 DIMETHYL 6 (METHYLAMINO)PYRIMIDINIUM CHLORIDE; AMLODIPINE; ANTIFUNGAL AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORLENTOR; CYTOCHROME P450 3A4; DILTIAZEM; IVABRADINE; MACROLIDE; NEFAZODONE; NICORANDIL; NITRIC ACID DERIVATIVE; PLACEBO; POTASSIUM CHANNEL STIMULATING AGENT; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG; VERAPAMIL; ZATEBRADINE; BENZAZEPINE DERIVATIVE; DRUG DERIVATIVE;

ADJUVANT THERAPY; ARTICLE; CARDIOTOXICITY; CHRONOTROPISM; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEART ARRHYTHMIA; HUMAN; IMMUNOPATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; RETINA DISEASE; RETINA INJURY; RISK BENEFIT ANALYSIS; SINUS BRADYCARDIA; STABLE ANGINA PECTORIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; ANGINA PECTORIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; EUROPE; METABOLISM; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; AMLODIPINE; ANGINA PECTORIS; ATENOLOL; BENZAZEPINES; CALCIUM CHANNEL BLOCKERS; COST-BENEFIT ANALYSIS; DRUG APPROVAL; EUROPE; HUMANS; RANDOMIZED CONTROLLED TRIALS; VERAPAMIL;

EID: 34248325329     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Prescrire Rédaction "Angor stable: quel médicament antiangoreux choisir?" Rev Prescrire 2000; 20 (205): 297-298.
2. "Treatment of stable angina". In: "Martindale The complete drug reference" 34th ed., The Pharmaceutical Press, London 2005: 813-814.
3. Prescrire Rédaction "vérapamil LP et angor stable: un recours dans certaines situations" Rev Prescrire 2000; 20 (208): 491-492.
4. Prescrixe Rédaction "Angor: la nifédipine ne modifie pas le pronostic" Rev Prescrire 2005; 25 (258): 132.
5. Nissen SE et al. "Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure" JAMA 2004; 292 (18): 2217-2226.
6. Snow V et al. "Primary care management of chronic stable angina and asymptornatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians" Ann Intern Med 2004, 141: 562-567.
7. Prescrire Rédaction "nicorandil et angor: effort très modeste" Rev Prescrire 2006; 26 (274): 497.
8. European Medicines Agency - CHMP "European Public Assessment Report - Corlentor - Scientific discussion" (First published): 45 pages; published on the EMEA website on 25 October 2005.
9. Borer JS et al. "Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina" Circulation 2003; 107 (6): 817-823.
10. f inhibitor, compared with atenolol in patients with chronic stable angina" Eur Heart J 2005; 26 (23): 2529-2536.
11. Commission européenne "Résumé des caractéristiques-Corlentor°" 25 October 2005: 23 pages.
12. Prescrire Rédaction "Les definitions cliniques de l'insuffisance cardiaque" Rev Prescrire 2000; 20 (211): 771.